Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Cash & Equivalents (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Cash & Equivalents for 7 consecutive years, with $3.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 51.0% to $3.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.1 million, a 51.0% decrease, with the full-year FY2024 number at $6.3 million, up 281.01% from a year prior.
  • Cash & Equivalents was $3.1 million for Q3 2025 at Vivos Therapeutics, down from $4.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $34.2 million in Q2 2021 to a low of $988000.0 in Q3 2023.
  • A 5-year average of $9.8 million and a median of $6.3 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 85.34% in 2022, then skyrocketed 537.65% in 2024.
  • Vivos Therapeutics' Cash & Equivalents stood at $24.0 million in 2021, then tumbled by 85.34% to $3.5 million in 2022, then crashed by 53.31% to $1.6 million in 2023, then soared by 281.01% to $6.3 million in 2024, then tumbled by 50.69% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Cash & Equivalents are $3.1 million (Q3 2025), $4.4 million (Q2 2025), and $2.3 million (Q1 2025).